Cancer immunotherapy with immune checkpoint inhibitors has been the focus of many studies since the efficacy of immunotherapy targeting the immune checkpoint molecule programmed cell death-1 (PD-1) and its ligand PD-L1 was demonstrated [6–11]. Here, PDCD1 is linked to cancer.